BioBase said this week that Cypher Genomics has selected its GenomeTrax database solution to help with interpreting genomic variants in next-generation sequencing data.
Cypher Genomics offers NGS analysis services for medical geneticists, computational biologists, clinicians, and researchers. BioBase’s Genome Trax lets users prioritize human genome variants in whole genome or exome data for further investigation. It also identifies novel mutations that are likely to affect the function of candidate disease genes, and enables users to filter out the millions of irrelevant variants.
According to BioBase, researchers at Cypher Genomics will incorporate data from Genome Trax’s knowledgebase into their variant analysis pipeline.
It “frees them to focus on their deep expertise in computer science, quantitative genetics, and medicine, to deliver state-of-the-art genome processing to their customers," Frank Schacherer, BioBase’s chief technology officer, said in a statement.
Genome Trax “provides the most comprehensive database of human disease associations," Ali Torkamani, Cypher Genomics’ chief science officer, said in a statement. It “is an invaluable resource in both clinical and research-grade genetics and genomics activities.”
Other recent Genome Trax customers include the Luxembourg Center for Systems Biomedicine, which is using the software to analyze next-generation sequencing data for use in clinical diagnostics (BI 7/20/2012).